Tacrolimus as a rescue immunosuppressant after heart and lung transplantation

Transplantation

Volumn 65, Issue 1, 1998, Pages 109-113

  Mentzer Jr , Robert M ^a   Jahania, M Salik ^a   Lasley, Robert D ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; OKT 3; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHUS STENOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONVULSION; DEPRESSION; DIARRHEA; DYSPNEA; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE;

ADULT; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; TACROLIMUS; UNITED STATES;

EID: 0344541764     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801150-00021     Document Type: Article

References (20)

1. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 4.
2. Goto T, Kino T, Hatanaka H, et al. FK 506: Historical perspectives. Transplant Proc 1991; 23: 2713.
3. Kino T, Inamura N, Sakai F, et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 1987; 19: 36.
4. Fung JJ, Starzl TE. FK 506 in solid organ transplantation. Transplant Proc 1994; 26: 3017.
5. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 295.
6. Armitage JM, Fricker FJ, Del Nido P, Cipriani L, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23: 3058.
7. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23: 3054.
8. Armitage JM, Fricker FJ, Del Nido P, Starzl TE, Hardesty RL, Griffith BP. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993; 105: 464.
9. Armitage JM, Kormos RL, Monta S, et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205.
10. Pham SM, Kormos RL, Murali S, et al. Cardiac transplantation at the University of Pittsburgh: 1994 update. Clin Transplant 1994; 121.
11. Armitage JM, Fricker FJ, Kurland G, et al. Pediatric lung transplantation: the years 1985 to 1992 and the clinical trial of FK 506. J Thoracic Cardiovasc Surg 1993; 105: 337.
12. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57: 848.
13. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580.
14. European FK506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423.
15. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
16. Swenson JM, Fricker FJ, Armitage JM. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. J Am Coll Cardiol 1995; 25: 1183.
17. Griffith BP, Hardesty RL, Armitage JM, et al. A decade of lung transplantation. Ann Surg 1993; 218: 310.
18. Bolman RM 3rd. Advantage - FK506: reduced chronic rejection for lung transplant recipients [Editorial]. Ann Thorac Surg 1995; 60: 495.
19. Wagner FM, Reichenspurner H, Uberfuhr P, et al. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? J Heart Lung Transplant 1994; 13: 438.
20. McAlister V, Grant D, Roy A, Yilmaz Z, Ghent C, Wall W. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression. Transplant Proc 1993; 25: 1400.